Bridge Biotherapeutics, a biotech company based in Seongnam, South Korea, has secured a significant funding of 25 billion won (approximately $183.3 million) from Parataxis, a crypto investment firm, to establish a Bitcoin treasury. The firm plans to rebrand as Parataxis Korea and will continue its trading on the KOSDAQ, the South Korean stock market. This strategic move is inspired by the rising interest in Bitcoin treasury approaches seen in other global companies, such as MicroStrategy in the U.S. and Metaplanet in Japan, which have adopted similar strategies to enhance institutional interest in cryptocurrencies. Metaplanet notably holds 10,000 BTC, making it a prominent publicly traded company outside North America with substantial Bitcoin holdings. This trend indicates a growing inclination among healthcare-related firms towards integrating Bitcoin as a treasury asset. The funding will facilitate the company's aim to navigate the evolving landscape of cryptocurrency investment, aligning with Parataxis's intentions of entering U.S. public markets through a special purpose acquisition company (SPAC) named SilverBox Corp IV.

Source 🔗